Evidence-based study design in ocular allergy trials

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 5, 2008, Pages 484-488

  Katelaris, Constance H ^a   Bielory, Leonard ^b  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Allergic conjunctivitis; Clinical trials; Conjunctival provocation tests; Ocular allergy

Indexed keywords

ANTAZOLINE; ANTIHISTAMINIC AGENT; CROMOGLYCATE DISODIUM; IMMUNOGLOBULIN E; MAST CELL DEGRANULATING PEPTIDE; PHENIRAMINE; PLACEBO;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; EYE ALLERGY; FOOD AND DRUG ADMINISTRATION; GIANT PAPILLARY CONJUNCTIVITIS; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; PERENNIAL ALLERGIC CONJUNCTIVITIS; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; VERNAL CONJUNCTIVITIS;

ALLERGENS; ANTI-ALLERGIC AGENTS; CLINICAL TRIALS AS TOPIC; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 53549125787     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32830e6b29     Document Type: Review

References (26)

1. Nathan HE, Meltzer O, Blachere FM, et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1999; 99:s808-s814.
2. Singh K, Bielory L Ocular allergy: a national epidemiologic study. J Allergy Clin Immunol 2007; 119 (Suppl 1):S154.
3. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhino conjunctivitis. Qin Exp Allergy 1991; 21:77-83.
4. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002; 3:541-553.
5. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11:17-33.
6. Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005; 12:233-242.
7. Ikeda H. Practice of pharmaceutical care: therapeutic drug monitoring and pharmacoeconomics of glaucoma. Yakugaku Zasshi 2007; 127:1441-1448.
8. Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the allergic rhinitis and its impact on asthma guideline 2008 update. Allergy 2008; 63:38-46.
9. Werner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317:1624-1629.
10. DeWester JE, Philpot E, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003; 24:331-337.
11. Bernstein DL, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004; 34:952-957.
12. Kaiser HB, Nacleno RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119:1430-1437.
13. Bielory L Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008; 100:272-279.
14. Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest Ophthalmol Vis Sci 2000; 41:3850-3855.
15. Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2:447-452.
16. Meltzer EO, Hamilos DL, Hadtey J A, et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006; 118:S17-S61.
17. Bhandan MJ, Busse W, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170:477-480.
18. Lexchin JL, Bero LA, Djulbegovic B, Dark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170.
19. Liss H. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J 2006; 8:451-454.
20. Connell JT. A novel method to assess antihistamine and decongestant efficacy. Ann Allergy 1979; 42:278-285.
21. Akerlund A, Andersson M, Leflein J, et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Qin Immunol 2005; 115:S460-S482.
22. Abelson MB. Comparison of the conjunctical allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmologica Scandinavica Suppl 1999; 228:38-42.
23. Moller C, Bjorksten B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984; 39:37-41.
24. Del Carpio J, Kabbash L, Turenne Y, e al. Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84:741-746.
25. Dark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007; 62:1023-1028. This paper discusses methodological aspects of assessing efficacy in clinical immunotherapy trials and this discussion is of relevance to clinical trials in ocular allergy in which rescue medication may be used.
26. Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treastment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998; 81:128-134.